$0.8252
0.03884.93%
Perspective Therapeutics Inc
CATXAMEX
Perspective Therapeutics fell 62.8% from $2.22 to $0.83, behind the S&P 500's +11.2%. Its worst day was Oct 23 (−28.8%), and its low came Nov 10 at $0.79.
Nov 11, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Perspective Therapeutics shares rose 66.4%, while the S&P 500 fell 0.2%.
+66.4%, the year's best day, on 80M shares, the year's heaviest volume · S&P 500 −0.2%
Perspective Therapeutics closed at its highest level of the year, 154.5% above where the year started.
Story events cover the past 12 months · Times ET
+12.3% · S&P 500 −0.3%
EPS of $-0.51 missed the $-0.35 estimate on $43,000.00 revenue (est. $254,188.00).
−5.2% · S&P 500 +0.3%
EPS of $-0.25 beat the $-0.30 estimate on $76,000.00 revenue (est. $179,744.00).
−2.8% · S&P 500 −0.2%
EPS of $-0.22 beat the $-0.27 estimate on $81,000.00 revenue (est. $113,960.00).
+6.0% · S&P 500 −0.3%
Perspective Therapeutics shares fell 28.8%, while the S&P 500 fell 0.5%.
−28.8%, the year's worst day · S&P 500 −0.5%
EPS of $-0.27 missed the $-0.24 estimate on $20,000.00 revenue (est. $78,248.00).
−8.1% · S&P 500 −0.4%
Where it ended: a close of $0.83 on Nov 11, 2026. Up next: Q4 2026 earnings on Feb 11, 2027 (EPS est. $-0.27, revenue est. $83,240.00).
Nothing in the past 12 months.
All CATX dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CATX and SPY from Benzinga historical bars. Not investment advice.
